Novo Nordisk’s next-gen metabolic drug CagriSema performed better than the blockbuster semaglutide at reducing blood sugar and weight in patients with type 2 diabetes.

That was the topline result from the latest Phase 3 readout …

Semaglutide erased the constant mental chatter about food that had ruled her life, but along with it went her awareness of basic needs.

The Food and Drug Administration (FDA) recently approved a tablet version of the GLP-1 drug Wegovy for weight loss. Image courtesy of Novo Nordisk

Research shows that people who stop taking GLP-1 medications regain weight within 2 years.

A new study has found that people regain weight within 2 years of stopping a GLP-1 drug.

Metabolic improvements also tend to fade within that time, researchers found.

A combination of hormone therapy and the GLP-1 drug tirzepatide may promote weight loss in postmenopausal females. Image Credit: Mauro Grigollo/Stocksy

A new study found that postmenopausal females who use hormone therapy in combination with tirzepatide experience greater weight loss compared to those who don’t. 

EU regulators have refused to greenlight Eli Lilly’s weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead for Novo Nordisk’s semaglutide in liver disease.

Lilly failed to …

Eli Lilly has budgeted $3.5 billion for a new weight loss injectable and device factory in Lehigh Valley, PA, which will manufacture its next-gen obesity drug retatrutide.

The factory will also produce other weight loss …

(MedPage Today) — Note that some links may require registration or subscription.
The United Kingdom’s Medicines and Healthcare Products Regulatory Agency strengthened its warnings on GLP-1 receptor agonists and dual GLP-1/GIP agonists to include…

(MedPage Today) — GLP-1 receptor agonist use was tied to a lower risk of recurrent major adverse limb events (MALEs) in people with diabetes compared with another drug class, a retrospective Taiwanese study showed.
Among 17,288 patients, new…

A renowned physician-scientist says treatment is not one-size-fits-all.

THURSDAY, Jan. 29, 2026 — Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with reduced postoperative revision following functional endoscopic sinus surgery (FESS) for up to five years among patients with chronic…

(MedPage Today) — Note that some links may require registration or subscription.
“Night owls” may be at higher risk of cardiovascular disease, but it mostly comes down to their overall health behaviors, according to a U.K. Biobank cohort study…

(MedPage Today) — Use of tirzepatide (Mounjaro, Zepbound) was tied to a reduced incidence of new or progressive diabetic retinopathy and fewer complications in patients with diabetes and overweight/obesity, a retrospective study suggested.
In…

Ozempic, Mounjaro, and Zepbound can drive impressive weight loss, but stopping them is often followed by rapid weight regain. Researchers found that people regain weight faster after quitting these drugs than after diet and exercise alone. Improvements in heart health and diabetes risk also tend to reverse within a few years. The results suggest long-term success may require more than medication alone.

(MedPage Today) — Tirzepatide (Mounjaro, Zepbound) users should never share KwikPens due to risk for transmission of blood-borne pathogens, the FDA warned in an updated label.
GLP-1 medications for weight loss accounted for more than 7% of all…

Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.

(MedPage Today) — Postmenopausal women on the GLP-1 medication tirzepatide (Zepbound) for obesity lost more weight if they were also using menopause hormone therapy, a retrospective cohort study indicated.
Among 120 women with overweight or obesity…

According to doctors, making a misstep is easier than you may think.

South San Francisco, CA — January 26, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP…

I’m a candidate for the meds, but they’re not for me—at least for now.

Novo, Regeneron and Pfizer all landed weight loss deals with China-based companies last year.

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause.

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

(MedPage Today) — Meals and snacks with “GLP-1 Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) to lose weight…

(MedPage Today) — The FDA requested that manufacturers of GLP-1 receptor agonists remove information regarding risks of suicidal behavior and ideation from drug labels following a detailed review of existing data, the agency announced on Tuesday…

(MedPage Today) — President Trump said he’s never taken GLP-1 receptor agonists but said he “probably should.” (New York Times)
People with diabetes and cancer lived longer and had lower hospitalization rates if they were taking GLP-1 drugs rather…

Audience: Health Care Professional, Consumer January 13, 2026

FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications
This information is an update to the FDA Drug Safety…

Bariatric surgery far outperformed GLP-1 weight loss drugs in a new real-world comparison of more than 50,000 patients. Two years after treatment, surgery patients lost about 58 pounds on average, while those using semaglutide or tirzepatide lost roughly 12 pounds. Even patients who stayed on GLP-1 drugs for a full year saw much smaller results than surgical patients. High dropout rates and real-world challenges appear to blunt the drugs’ effectiveness.